MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format
28 avr. 2020 16h01 HE
|
MacroGenics, Inc.
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call
28 avr. 2020 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting
27 avr. 2020 00h05 HE
|
MacroGenics, Inc.
Rockville, MD, April 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Departure of Chief Medical Officer
04 mars 2020 17h00 HE
|
MacroGenics, Inc.
Rockville, MD, March 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
27 févr. 2020 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and 2019 Financial Results
25 févr. 2020 16h01 HE
|
MacroGenics, Inc.
Margetuximab: BLA for metastatic HER2-positive breast cancer accepted for review by the FDA; Phase 2/3 MAHOGANY study ongoing in front-line advanced HER2-positive gastric cancerFirst clinical data...
MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call
13 févr. 2020 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, Feb. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
10 févr. 2020 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 10, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Present at the J.P. Morgan Healthcare Conference
13 janv. 2020 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Outlines Corporate Priorities for 2020
09 janv. 2020 16h30 HE
|
MacroGenics, Inc.
Rockville, MD, Jan. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...